Zhang / Surapaneni ADME-Enabling Technologies in Drug Design and Development

1. Auflage 2012
ISBN: 978-1-118-18074-7
Verlag: John Wiley & Sons
Format: PDF
Kopierschutz: Adobe DRM (»Systemvoraussetzungen)

E-Book, Englisch, 800 Seiten, E-Book

A comprehensive guide to cutting-edge tools in ADME research
The last decade has seen tremendous progress in the developmentof analytical techniques such as mass spectrometry and molecularbiology tools, resulting in important advances in drug discovery,particularly in the area of absorption, distribution, metabolism,and excretion (ADME).
ADME-Enabling Technologies in Drug Design and Developmentfocuses on the current state of the art in the field, presenting acomprehensive review of the latest tools for generating ADME datain drug discovery. It examines the broadest possible range ofavailable technologies, giving readers the information they need tochoose the right tool for a given application, a key requisite forobtaining favorable results in a timely fashion for regulatoryfilings. With over thirty contributed chapters by an internationalteam of experts, the book provides:
* A thorough examination of current tools, covering bothelectronic/mechanical technologies and biologically based ones
* Coverage of applications for each technology, including keyparameters, optimal conditions for intended results, protocols, andcase studies
* Detailed discussion of emerging tools and techniques, from stemcells and genetically modified animal models to imagingtechnologies
* Numerous figures and diagrams throughout the text
Scientists and researchers in drug metabolism, pharmacology,medicinal chemistry, pharmaceutics, toxicology, and bioanalyticalscience will find ADME-Enabling Technologies in Drug Design andDevelopment an invaluable guide to the entire drug developmentprocess, from discovery to regulatory issues.

Autoren/Hrsg.

Zhang, Donglu

Surapaneni, Sekhar

Über Autor(innen)

Donglu Zhang, PhD, is a Principal Scientist in Pharmaceutical Candidate Optimization at Bristol-Myers Squibb in Princeton, New Jersey. He has published seventy peer-reviewed articles, codiscovered the Mass Defect Filtering technique, and coedited two books.
Sekhar Surapaneni, PhD, is Director, DMPK, at Celgene Corporation in New Jersey. He has published extensively in peer-reviewed journals and is a member of ISSX and ACS.